Investors should monitor upcoming Phase 2a initiation in 2Q 2026 and further data readouts from higher-dose cohorts. The differentiated profile vs. GLP-1s could position WVE-007 as a maintenance or combination therapy, creating significant commercial upside.
WVE drugs
WVE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 26 $6.20entry
- T+1 · 8mo ago +2.74%α +4.42% · $6.37
- T+5 · 8mo ago +17.42%α +15.79% · $7.28
- T+20 · 7mo ago +15.81%α +5.14% · $7.18
- T+60 · 5mo ago +0.97%α −12.98% · $6.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Wave Life Sciences released positive Phase 1 data for WVE-007, an investigational obesity treatment, showing significant and durable reductions in visceral fat (-14% vs. placebo) and improved body composition six months after a single dose. The results support advancement into Phase 2a trials in higher-BMI patients in 2Q 2026 and suggest potential in MASH, type 2 diabetes, and cardiovascular disease. The therapy continues to show a favorable safety profile.
Key Facts
- Single 240 mg dose of WVE-007 led to -14.3% placebo-adjusted reduction in visceral fat at 6 months (p<0.05)
- Total fat reduced by -5.3%, waist circumference by -3.3%, body weight by -0.9%, with lean mass preserved (+2.4%)
- Visceral fat-to-muscle ratio (VMR) improved by -16.5%, outperforming semaglutide's -12.2% in a higher-BMI population
- Serum Activin E suppressed up to 88%, supporting potential for once- or twice-yearly dosing
- WVE-007 remains generally safe and well tolerated with no severe or serious treatment-related adverse events
- Phase 2a trial in patients with BMI 35-50 kg/m² expected to initiate in 2Q 2026
Financial Impact
High potential long-term revenue if WVE-007 succeeds in obesity and related metabolic diseases; competitive advantage due to muscle-preserving fat loss and infrequent dosing
Risk Factors
- Phase 1 results are in lower-BMI individuals; efficacy may not translate to higher-BMI populations in Phase 2a
- Development timeline remains long, with key data not expected until 2026-2027
- Competition from established and emerging obesity therapies is intense
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262889 |
Track record
16 reports on WVE
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +4.86% at T+1 after the Sep 30, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
- Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
- Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
- May 18, 202626w ago Press Release Bullish 7/10 Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
- Apr 28, 202628w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers